Efficacy of vitamin D supplementation in children with attention deficit hyperactivity disorder
- Conditions
- attention deficit hyperactivity disorder.Disturbance of activity and attention
- Registration Number
- IRCT201404222394N10
- Lead Sponsor
- Vice Chancellor for Research, Iran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Signed parental (mother/father) informed consent; 6-12 years old children; Newly diagnosed attention deficit hyperactivity disorder children by child and adolescent psychiatrist; BMI percentile between 5 to 85. Exclusion criteria: History or current diagnosis of other psychiatric diseases (e.g., autism, bipolar disorder, major depression disorder, etc.) by psychiatrist; History or current diagnosis of neurological condition (e.g., epilepsy, brain tumors, etc.) by psychiatrist; History or current diagnosis of any serious systemic (e.g., diabetes, hyper/hypothyroidism, etc.); History of major head trauma ; Diagnosis of Mental retardation; Any medicine administration at least 4weeks before the initiation of the study; Any vitamin D products (enriched products with vitamin D) at least 3 months before the initiation of the study; Any supplement use containing antioxidants like multivitamin, vitamin A,C,E at least 2 months before the initiation of the study.
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Symptoms of disease. Timepoint: week 0,4 and 8. Method of measurement: Parental Conners questionnaire.
- Secondary Outcome Measures
Name Time Method Symptoms in morning and evening. Timepoint: week 0,4 , 8. Method of measurement: Morning-evening symptoms questionnaire.;Adverse drug effects. Timepoint: week 4,8. Method of measurement: Adverse drug effects questionnaire.;Serum level of Malondialdehyde. Timepoint: week 0,8. Method of measurement: blood test.;Serum level of 8-hydroxydeoxyguanosine. Timepoint: week 0,8. Method of measurement: blood test.;Serum level of 25-hydroxyD. Timepoint: week 0,8. Method of measurement: blood test.